Drug intelligence / Profile preview

PA1010

Development stage: Phase 2
Lead developer: Apeloa
Modality: Small Molecules
Administration: Oral

Overview

PA1010 is an investigational small molecule drug developed by Zhejiang Palo Alto Pharmaceuticals for the treatment of chronic hepatitis B. It is currently in Phase 1/2 clinical development, with studies evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with chronic hepatitis B. The specific mechanism of action has not been disclosed publicly. The drug is administered orally and aims to address unmet needs in the management of chronic hepatitis B infection[1][3].

Beyond the preview

Go deeper on PA1010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PA1010.

Explore the full profile